Lower GI 2017

RAPIDO-Trial (randomized phase III) MRI-defined high-risk criteria: cT4 or MRF+ or N2 or lateral N+ or EMVI+

Wk 14-16

(Optional) CAPOX 8#, q21

T M E

RT 50.4 Gy + Capecitabine 825 mg/m 2 bid

R

Wk 22-24

T M E

5 x 5 Gy

CAPOX 6#, q21

Primary endpoint: 3y-DFS (50% > 60%), 885 pts. required